ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

Key Inclusion Criteria:

• CD20-positive B-cell NHL that is persistent or progressive after having received atleast 2 prior systemic therapies per NCCN guidelines

• At least 1 measurable lesion according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 or subjects withECOG scores of 2 with a serum albumin of >3.5

• Adequate hematologic and renal, hepatic, and cardiac function

• Oxygen saturation via pulse oxygenation ≥ 92% at rest on room air

Key Exclusion Criteria:

• Prior treatment with a genetically modified cell therapy product targeting CD20

• Autologous stem cell transplant within 6 weeks of informed consent or history ofallogeneic stem cell transplantation

• History of central nervous system (CNS) lymphoma or primary CNS lymphoma

• History or presence of clinically relevant CNS disorder (e.g. epilepsy)

• Clinically significant active infection

• Currently active, clinically significant cardiovascular disease

• Human Immunodeficiency virus (HIV) infection (however, subjects on anti-retroviraltherapy for at least 4 weeks and with HIV viral loads of <400 copies/mL areeligible), active hepatitis B infection, or hepatitis C infection

• History of other malignancies with the exception of certain treated malignancieswith no evidence of disease

• Primary immunodeficiency disorder

• Pregnant or lactating female

• Any medical, psychological, familial, or sociological conditions that, in theopinion of the Investigator or Sponsor Medical Monitor, would impair the ability ofthe subject to receive study treatment, comply with study requirements, orunderstanding of the informed consent